Lackamp Nadine, Wilkemeyer Ina, Jelas Ivan, Keller Ulrich, Bullinger Lars, Stintzing Sebastian, le Coutre Philipp
Department of Hematology, Oncology, and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Department of Urology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Front Oncol. 2021 Nov 5;11:772809. doi: 10.3389/fonc.2021.772809. eCollection 2021.
Progress in oncological treatment has led to an improved long-term survival of young male cancer patients over the last decades. However, standard cancer treatments frequently implicate fertility-damaging potential. Cryopreservation of sperm is the current standard option to preserve patient's fertility after treatment, yet long-term data on usage and reproductive experiences is still limited. Natural fertility after treatment and especially in relation to the type of treatment has been poorly analyzed so far. Therefore, we performed a retrospective survey including male patients with an indication for gonadotoxic treatment who cryopreserved reproductive material at our institution between 1994 and 2017. Study questionnaires regarding treatment, material usage, and reproductive outcomes were sent to eligible patients. Additionally, semen analyses of study participants from the time of cryopreservation were evaluated. A total of 99 patients were included in the study. Respondents' median age was 38.0 years. Most frequent diagnoses were testicular cancer (29.3%) and lymphoma (26.3%). A further 8.1% suffered from autoimmune diseases. Testicular cancer patients had a significantly lower pre-treatment median sperm concentration (18.0 million/ml) compared to non-testicular cancer patients (54.2 million/ml). Until November 2020, the determined sperm usage and cumulative live-birth rate per couple were 17.2% and 58.8%, respectively. Most sperm users received treatments with high (40.0%) or intermediate (33.3%) gonadotoxic potential. 20.7% of all patients reported to had fathered at least one naturally conceived child after treatment, this being the case especially if they had been treated with less or potentially gonadotoxic therapies. In conclusion, our findings emphasize the importance of sperm cryopreservation in the context of male fertility preservation. Furthermore, they indicate that the gonadotoxic potential of patients' treatments could represent a predictive factor for sperm usage.
在过去几十年中,肿瘤治疗的进展使年轻男性癌症患者的长期生存率得到了提高。然而,标准的癌症治疗常常具有损害生育能力的潜在风险。精子冷冻保存是目前治疗后保留患者生育能力的标准选择,但关于其使用情况和生殖体验的长期数据仍然有限。到目前为止,对治疗后自然生育能力,尤其是与治疗类型相关的自然生育能力分析不足。因此,我们进行了一项回顾性调查,纳入了1994年至2017年间在我们机构冷冻保存生殖材料、有性腺毒性治疗指征的男性患者。向符合条件的患者发送了关于治疗、材料使用和生殖结局的研究问卷。此外,还评估了研究参与者冷冻保存时的精液分析结果。共有99名患者纳入研究。受访者的中位年龄为38.0岁。最常见的诊断是睾丸癌(29.3%)和淋巴瘤(26.3%)。另有8.1%的患者患有自身免疫性疾病。与非睾丸癌患者(5420万/毫升)相比,睾丸癌患者治疗前的中位精子浓度显著较低(1800万/毫升)。截至2020年11月,确定的精子使用率和每对夫妇的累积活产率分别为17.2%和58.8%。大多数使用精子的患者接受了具有高(40.0%)或中度(33.3%)性腺毒性潜力的治疗。所有患者中有20.7%报告在治疗后至少自然生育了一个孩子,尤其是在接受了较少或潜在性腺毒性治疗的情况下。总之,我们的研究结果强调了精子冷冻保存在男性生育力保留中的重要性。此外,研究结果表明患者治疗的性腺毒性潜力可能是精子使用的一个预测因素。